DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184337

Doxycycline induced fixed drug eruption: a case report

Isswariya Anandan, Nitya Selvaraj, Suganya Ganesan, Meher Ali Rajamohammad, Nalinidevi Jayabalan

Abstract


Fixed drug eruption (FDE) is an adverse drug reaction seen with various groups of drugs are antibiotics such as trimethoprim -sulphamethoxazle, pencillin, tetracyclines, non steroidal anti- inflammatory drugs like ibuprofen, aspirin etc. Doxycycline belongs to tetracycline groups of antibiotics. We herein present the case of Doxycycline induced fixed drug eruption. A 35-year - old man presented to our hospital, with a 2-day history of itching and hyperpigmentation over the chest. Patient developed skin lesion 2 days after and he started taking Doxycycline 100 mg twice a day for skin infections. Dermatological examination revealed multiple well defined hyperpigmented patches seen over the anterior aspect of the chest. Doxycycline was discontinued immediately, and the skin lesions resolved spontaneously within 2 weeks. Causality assessment by using Naranjo adverse drug reaction probability scale and WHO Uppsala monitoring scale categorize the reaction as Doxycycline was the probable cause for the adverse drug reaction. Severity assessment by using modified Hartwig and Siegel ADR severity assessment scale labelled the reaction as mild-level 2. The causative drug or drugs and cross reactants should be avoided in future to prevent recurrence of similar skin reactions.


Keywords


Antibiotic, Doxycycline, Fixed drug eruption, Tetracycline

Full Text:

PDF

References


Pai VV, Bhandari P, Kikkeri NN, Athanikar SB, Sori T. Fixed drug eruption to fluconazole: A case report and review of literature. Indian J Pharmacol. 2012;44:643-5.

Lee AY. Fixed Drug Eruptions: Incidence, recognition, and avoidance. Am J clin Dermatol. 2000;1(5):277-85.

Podder I, Chandra S, Das A, Gharami RC. Doxycycline induced generalized bullous fixed drug eruption. Indian journal of dermatology. 2016 Jan;61(1):128.

Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379-407.

Nitya s, Deepa K, Mangaiarkkarasi A, Karthikeyan K. Doxycycline induced generalized bullous fixed drug eruption - A case report. J Young Phar. 2013;5(4):195-6.

Jain PS, Jain PA. Bullous, Fixed Drug Eruption to Ciprofloxacin: A case report. J clin Diagn Res. 2013 Apr;7(4):744-5.

Das A, Sancheti K, Podder I, Das NK. Azithromycin induced bullous fixed drug eruption. Indian J Pharmacol. 2016;48:83-5.

Sehgal VN, Srivastava G. Fixed drug eruption (FDE). Changing scenario of incriminating drugs. Int J Dermatol. 2006;45:897-908.

Lim WK, Kim DH, Jin SY, Choi YS, Lee SH, Huh HJ, et al. A Case of Fixed Drug Eruption Due to Doxycycline and Erythromycin Present in Food. Allergy Asthma Immunol Res. 2013 Sep;5(5):337-9.

Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P. Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol. 1997;36:782-4.

Dewdney JM, Maes L, Raynaud JP, Blanc F, Scheid JP, Jackson T, et al. Risk assessment of antibiotic residues of beta-lactams and macrolides in food products with regard to their immuno-allergic potential. Food Chem Toxicol. 1991;29:477-83.

Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, et al. Prognosis of generalized bullous fixed drug eruption: Comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013;168:726-32.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available at: http://www.who-umc.org/Graphics/24734.pdf. Accessed on 2018 Aug 04.